Factor VIII PEG Oxime Conjugates for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering active agents like polypeptides face challenges such as short half-life, immune responses, and inconvenience due to frequent injections. Additionally, conjugation of polymers to active agents can interfere with pharmacologic activity and require harsh reaction conditions.
Innovation Solution
The development of conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, specifically polyethylene glycol (PEG), which is oxidized and then coupled with a PEG oxyamine reagent, allowing for stable and bioactive conjugate formation without significant loss of activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides are delivered via injection to avoid proteolytic degradation, then bioactivity is preserved, but half-life is short and frequent injections are required
Solution Approach 1:
The patent modifies the chemical structure of Factor VIII by conjugating water-soluble polymers (PEG, dextran, hydroxyethyl starch) to carbohydrate moieties on the protein. This parameter change in molecular structure extends half-life from minutes to hours while preserving bioactivity through controlled conjugation at specific sites
Solution Approach 2:
The invention creates composite conjugates combining Factor VIII protein with water-soluble polymers. The polymer-protein composite structure provides both the bioactivity of the original polypeptide and the extended circulation time of the polymer, resolving the contradiction between maintaining bioactivity and extending half-life
2Duration of action of moving object
If polymers are conjugated to active agents to extend half-life, then dosing frequency is reduced, but pharmacologic activity may be interfered with
Solution Approach 1:
The patent applies local quality by selectively conjugating polymers to specific carbohydrate moieties at defined locations on the Factor VIII molecule rather than random conjugation. This localized modification extends half-life while preserving the active sites and pharmacologic function of the protein
Solution Approach 2:
The invention uses carbohydrate moieties as intermediary attachment points between the polymer and protein. This intermediary approach allows polymer conjugation without direct modification of the protein's active sites, maintaining pharmacologic activity while achieving extended half-life
3Ease of manufacture
If conventional conjugation methods are used to attach polymers to active agents, then conjugate formation is achieved, but harsh reaction conditions are required
Solution Approach 1:
The patent employs carbohydrate moieties as natural intermediary attachment points that enable polymer conjugation under mild conditions. This eliminates the need for harsh reaction conditions by utilizing the inherent chemical properties of carbohydrate groups on the protein surface
Solution Approach 2:
The invention utilizes the protein's own carbohydrate moieties as the conjugation sites, making the protein self-sufficient for the conjugation process. This self-service approach eliminates the need for external harsh reagents or conditions, allowing conjugate formation under physiological-like conditions
4Reliability
If frequent injections are administered to maintain therapeutic levels, then pharmacodynamic activity is sustained, but patient convenience is reduced and pain is increased
Solution Approach 1:
The patent changes the molecular parameters of Factor VIII through polymer conjugation, extending half-life from minutes to hours. This parameter change transforms the dosing regimen from frequent injections to less frequent administration, improving patient convenience while maintaining therapeutic activity
Solution Approach 2:
The invention applies partial action by providing just enough polymer conjugation to extend half-life sufficiently for reduced dosing frequency. This partial modification achieves the desired therapeutic effect without over-modification that could compromise bioactivity, balancing efficacy with dosing convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting PEG-oxime-Factor VIII conjugates exhibit extended half-lives, reduced immunogenicity, and maintained or improved bioactivity, requiring less frequent dosing and minimizing adverse immune responses.
Implementation Method 1
a water-soluble polymer such as a polyethylene glycol is covalently attached via an oxime linkage to an oxidized carbohydrate moiety of a Factor VIII molecule
Implementation Method 2
the linkage between the Factor VIII moiety and the water-soluble polymer comprises an oxime (CH═N—O)
Data Source
AI summary
The present disclosure provides conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, such as for example, a polyethylene glycol polymer. Methods for preparing and for administering such conjugates, are also provided, as are water-soluble polymer oxyamine reagents useful for preparing the subject conjugates, among other things.